Trial Profile
Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics
- 24 Jan 2019 Status changed from active, no longer recruiting to completed.
- 03 May 2018 Status changed from recruiting to active, no longer recruiting.
- 02 May 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.